ranolazine has been researched along with Innate Inflammatory Response in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Edwards, BS; Graves, SW; Saunders, MJ; Sklar, LA; Zhu, J | 1 |
| Binder, CJ; Ciotu, CI; Fischer, MJM; Goederle, L; Hengstenberg, C; Hohensinner, PJ; Huber, K; Kaun, C; Krivaja, Z; Krychtiuk, KA; Lenz, M; Podesser, BK; Rauscher, S; Rehberger Likozar, A; Salzmann, M; Sebestjen, M; Speidl, WS; Wojta, J | 1 |
| Cerri, C; Colucci, P; Corsi, F; Ferraro, E; Gabellini, C; Lai, M; Leigheb, M; Maya-Vetencourt, JF; Piano, I; Puppi, D; Vitolo, S; Votta, A | 1 |
| El-Gawly, HW; El-Sherbeeny, NA; Elaidy, SM; Elkholy, SE; Toraih, EA | 1 |
| Abacioglu, N; Chukwunyere, U; Sehirli, AO | 1 |
| Davangeri, R; Hashilkar, NK; Majagi, SI; Naveena, R | 1 |
| Bonaca, MP; Braunwald, E; Kakkar, R; Kohli, P; Kudinova, AY; Lee, RT; Morrow, DA; Murphy, SA; Sabatine, MS; Scirica, BM | 1 |
7 other study(ies) available for ranolazine and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Proteins; High-Throughput Screening Assays; Humans; Inflammation; Kinetics; Microspheres; Peptide Hydrolases; Peptides; Reproducibility of Results; Temperature | 2010 |
Pharmacologic modulation of intracellular Na
Topics: Acute Coronary Syndrome; Animals; C-Reactive Protein; Cardiovascular Agents; Coronary Artery Disease; Endothelial Cells; Humans; Inflammation; Mice; Ranolazine; Sodium; Sodium Channel Blockers | 2022 |
Anti-inflammatory reprogramming of microglia cells by metabolic modulators to counteract neurodegeneration; a new role for Ranolazine.
Topics: Anti-Inflammatory Agents; Humans; Inflammation; Lipopolysaccharides; Microglia; Neurodegenerative Diseases; Neuroprotective Agents; Quercetin; Ranolazine | 2023 |
Neuroprotective effects of ranolazine versus pioglitazone in experimental diabetic neuropathy: Targeting Nav1.7 channels and PPAR-γ.
Topics: Animals; Behavior, Animal; Comorbidity; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet, High-Fat; Hyperalgesia; Inflammation; Interleukin-1beta; Male; NAV1.7 Voltage-Gated Sodium Channel; Neuroprotective Agents; Pioglitazone; PPAR gamma; Ranolazine; Rats; Rats, Wistar; Spinal Cord; Tumor Necrosis Factor-alpha | 2020 |
COVID-19-related arrhythmias and the possible effects of ranolazine.
Topics: Action Potentials; Angina, Stable; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; COVID-19; COVID-19 Drug Treatment; Cytokines; Hemodynamics; Humans; Inflammation; Potassium Channels; Ranolazine; Sodium Channel Blockers | 2021 |
Effect of anti-inflammatory activity of ranolazine in rat model of inflammation.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carrageenan; Edema; Granuloma, Foreign-Body; Gum Arabic; Inflammation; Male; Random Allocation; Ranolazine; Rats, Wistar | 2018 |
Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial.
Topics: Acetanilides; Acute Coronary Syndrome; Aged; Biomarkers; Cardiovascular Diseases; Electrocardiography; Female; Heart Failure; Hemodynamics; Humans; Inflammation; Interleukin-1 Receptor-Like 1 Protein; Male; Natriuretic Peptide, Brain; Piperazines; Prognosis; Randomized Controlled Trials as Topic; Ranolazine; Receptors, Cell Surface; Risk Assessment | 2012 |